Valuation : Scholar Rock Holding Corporation

Market Cap 6.78B 5.83B 5.5B 5.01B 9.37B 648B 9.45B 65.52B 25.22B 329B 25.46B 24.9B 1,044B P/E 2026 *
-17.1x
P/E 2027 * -21.6x
Enterprise Value 6.46B 5.56B 5.24B 4.78B 8.93B 618B 9.01B 62.45B 24.04B 313B 24.27B 23.74B 995B EV / Sales 2026 *
1,137x
EV / Sales 2027 * 43.6x
Free-Float
99.23%
Yield 2026 *
-
Yield 2027 * -
1 day+1.92%
1 week-0.48%
Current month-1.99%
1 month+7.28%
3 months+26.26%
6 months+24.32%
Current year+26.38%
1 week 53.86
Extreme 53.86
57.79
1 month 51.5
Extreme 51.5
61.76
Current year 38.75
Extreme 38.75
61.76
1 year 27.07
Extreme 27.07
61.76
3 years 5.94
Extreme 5.94
61.76
5 years 4.32
Extreme 4.325
61.76
10 years 4.32
Extreme 4.325
70
Manager TitleAgeSince
Chief Executive Officer 59 27/04/2025
Director of Finance/CFO 62 27/04/2025
Chief Operating Officer 58 27/04/2025
Director TitleAgeSince
Chairman 59 01/07/2017
Director/Board Member 53 01/08/2014
Director/Board Member 78 01/10/2016
Date Insider Type Main position Quantity % Market Cap. Importance
01/07/26 Sell

Director

-2,544 0.0022%
01/07/26 Sell

Director

-5,446 0.0047%
01/07/26 Sell

Director

-3,053 0.0027%
Change 5-day change 1-year change 3-year change Capi.($)
+1.92%-0.48%+78.20%+805.20% 6.78B
-0.25%-1.36%+44.08%+102.76% 68.24B
+0.05%-4.16%+30.79%+74.17% 62.23B
-1.18%+0.47%-12.78%+384.69% 27.8B
-1.64%-5.00%+29.78%+9.41% 24.86B
-1.76%-6.30%-4.55%-19.75% 24.22B
-0.07%-3.88%+14.25%-19.71% 19.36B
-1.86%-2.22%+202.03%+353.89% 17.28B
-1.85%-4.86%-5.21%+496.16% 14.46B
-1.54%-2.88%+52.33%+159.75% 14.23B
Average -0.82%-3.02%+42.89%+234.66% 27.95B
Weighted average by Cap. -0.71%-3.04%+36.38%+152.86%

Financials

2026 *2027 *
Net sales 5.68M 4.89M 4.61M 4.2M 7.85M 543M 7.93M 54.93M 21.14M 276M 21.34M 20.88M 876M 146M 126M 119M 108M 202M 13.97B 204M 1.41B 544M 7.09B 549M 537M 22.51B
Net income -425M -366M -345M -314M -588M -40.67B -593M -4.11B -1.58B -20.63B -1.6B -1.56B -65.52B -364M -313M -295M -269M -503M -34.78B -507M -3.52B -1.35B -17.64B -1.37B -1.34B -56.04B
Net Debt -317M -273M -257M -234M -438M -30.32B -442M -3.06B -1.18B -15.38B -1.19B -1.16B -48.85B -405M -348M -329M -299M -560M -38.71B -565M -3.91B -1.51B -19.63B -1.52B -1.49B -62.37B
Logo Scholar Rock Holding Corporation
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
Employees
289
Date Price Change Volume
10/09/26 $55.67 +1.92% 1,175,641
09/09/26 $54.62 -4.88% 1,601,822
08/09/26 $57.42 +3.78% 1,836,181
04/09/26 $55.33 -1.09% 658,048
03/09/26 $55.94 -0.29% 803,486
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
55.67USD
Average target price
60.75USD
Spread / Average Target
+9.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SRRK Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!